Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
$24.95
$0.55(10.50%)
At close: 4:00 PM EST
$24.95
$0.55(10.50%)
Day’s Range― - ―
52-Week Range$2.86 - $36.26
Previous CloseN/A
Volume1.27M
Average Volume (3M)1.18M
Market Cap
$1.84B
Enterprise Value$1.77B
Total Cash (Recent Filing)$328.96M
Total Debt (Recent Filing)$4.48M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Mar 02, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding78,659,920
10 Day Avg. Volume1,391,039
30 Day Avg. Volume1,182,916
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)0.84
Price to Sales (P/S)0.00
P/FCF Ratio-3.28
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.79K
Enterprise Value/Ebitda-10.94
Forecast
1Y Price Target
$43.20Price Target Upside73.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Class Readthrough And Commercial OpportunityPositive Phase 3 results for a rival oral SERD in the adjuvant setting strengthen confidence in the class and improve prospects for palazestrant to expand into a larger adjuvant market with partner support.
Combination Therapy AdvantageCombining palazestrant with ribociclib may provide a therapeutic edge because ribociclib has demonstrated survival benefit in first-line metastatic treatment, potentially improving the combo's trial results.
Drug DifferentiationPalazestrant's continuous oral estrogen receptor antagonism is seen as pharmacologically differentiated, which could translate into stronger clinical benefit versus competing SERDs.
Bears Say
Report Objectivity And Rating RiskPotential business relationships tied to firms publishing supportive reports and a Buy/High-Risk rating raise concerns about report objectivity and signal elevated investor risk.
Sentiment-driven Share VolatilityNegative outcomes from a competitor's trial could trigger steep, sentiment-driven downside for the company's shares regardless of internal program merits.
Trial Enrollment RiskDemonstrating success in patients without a key resistance mutation depends on enrolling enough of those patients, creating a material clinical trial risk that could hinder result interpretation.
Olema Pharmaceuticals News
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $2.86 and its highest was $36.26 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $1.84B.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 02, 2026 which is in 18 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 11, 2025. The company reported -$0.49 earnings per share for the quarter, missing the consensus estimate of -$0.475 by -$0.015.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 78,659,920 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.49 in its last earnings report, missing expectations of -$0.475. Following the earnings report the stock price went down -5.862%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.20 (73.15% Upside)
$43.20 (73.15% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $23.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
338.48%
12-Months-Change
Fundamentals
Return on Equity
-59.22%
Trailing 12-Months
Asset Growth
53.13%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
OLMA Stock 12 Month Forecast
Average Price Target
$43.20
▲(73.15% Upside)
Technical Analysis
Meiragtx Holdings
―
Arvinas Holding Company
―
Gossamer Bio
―
Keros Therapeutics
―
Compass Therapeutics
―
Ownership Overview
Currently, No data available
---